{"name":"BlueRock Therapeutics","slug":"bluerock-therapeutics","ticker":"","exchange":"","domain":"bluerock.com","description":"BlueRock Therapeutics is a clinical-stage biotechnology company focused on developing engineered cell therapies for the treatment of severe diseases with high unmet medical need. The company's lead programs are in the areas of neurology and cardiology, leveraging its proprietary Cell+Gene platform to create allogeneic cell therapies that can be administered off-the-shelf.","hq":"","founded":0,"employees":"~200","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"MSK-DA01","genericName":"MSK-DA01","slug":"msk-da01","indication":"Other","status":"phase_1"},{"name":"OpCT-001","genericName":"OpCT-001","slug":"opct-001","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"MSK-DA01","genericName":"MSK-DA01","slug":"msk-da01","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"OpCT-001","genericName":"OpCT-001","slug":"opct-001","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE1IWGt0aHk5LV9Ra2l3Z2FqQXB5am1RODZZaVIydHJvM2ZMX2R6bFJ4R0VGWjAwU25CdkYzY1VocnAwcGpTcnJTNXhYVU9zanB6Sk5pbE9NVk1OMURLeHM3VEdkWGRlcnPSAWxBVV95cUxOV05WRWNUVmU1Zy1QRzNXQlBwQjlUb2xieU91ekx1SmNQcXEwQ2dxVkxtaThLd21uUzFiaE1pWEVZVVJ3dUQ1RjNTelpyb3hyLVlHa3ZyT3Y5c0ZTQUM2MFRaTFNEYkp2X2E0N3c?oc=5","date":"2026-03-05","type":"pipeline","source":"BioInformant","summary":"The Pipeline for iPSC-Derived Cell Therapeutics in 2026 - BioInformant","headline":"The Pipeline for iPSC-Derived Cell Therapeutics in 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNQXhwMFVGeEZwX3lRMTI3UzBzekE5WUFyS25Fb0NNbno5NVVEb29oeElKdEFTV3JiVkU5LUxvbzQ0MTA5N0pCTXFmdlBEak1qaXdEUmNhOUxockhxaDBiREUybVoyX1VPdlhwaElUVU5ucXFhRlY1bzhKQ05lNDZUR9IBlAFBVV95cUxPYjk5Z1dNaGxXSWxZdURCbmFWV051d3phSElJYzNoVDRlMkgzMG1POGxBc2luVnM3cVY4Yk5iX3FQX28zS09Ed2lWalZlZ2VCOHp0R0VmeG01U3NTU0hUM1kwUGZzbkMzOFBMX3ZtRTQ4MmtoSjdlQndON1VEQlhYc0FidkdKMnl3OFJXcFRhdU9HOXk5?oc=5","date":"2026-01-23","type":"deal","source":"Chosunbiz","summary":"Bayer accelerates pipeline to beat patent cliff and eyes Korea partnerships - CHOSUNBIZ - Chosunbiz","headline":"Bayer accelerates pipeline to beat patent cliff and eyes Korea partnerships - CHOSUNBIZ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgJBVV95cUxNTEg2cFIxV3hzOTFYUmpnLVFHeDRDSWZ0RGdiLXlLODF3ZGhaang1ZmxiNFhrbEFrYlJqOEVaYXhxd3l2djc2N3g0LXdVYlRJckRxTW1tanZZYkpTWk52aTJnZTJ0bVhHMVdOMEpFeXFleTFYaGZybWljMmFvQ2JuWnVWcndFc1UxaUZnUkVFQVh2TmdhazAteEg4cGxLUlYzenpTQWpLSk4yUTRSQkVXekdNY3AzWTV4WlV5cEhlVEcxOG50dDJDb0tNcHZHckExRGVsb29WZXRVMVd1UU95WFZUWmlVa1JWQmZGRTRFLWRKZDRFN0xxb0EtREFWQmhubFZhNEVhV1lDNTdjZThWUEZVT1pzdDZXbnREQ1lGaF9GQ0pqR2c?oc=5","date":"2025-12-17","type":"pipeline","source":"Bayer","summary":"BlueRock Therapeutics investigative cell therapy bemdaneprocel for treating Parkinson’s disease receives Pioneering Regenerative Medical Product designation in Japan - Bayer","headline":"BlueRock Therapeutics investigative cell therapy bemdaneprocel for treating Parkinson’s disease receives Pioneering Rege","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxONjNxVGc1Y2s5MW9jcFg2WGo4QTVPQkVnVnNiUE9QZzRuQkVmdDU4bFJaM1hESDE0ZEI3eUlZMkI5X1lTM3BYRWMxMEU2cWFDcmdHOTR1U2VpSUYyTHJ0RGVFRzhVT1pqTUl3RVFCTHh4RXM0V1h0Wm1yQ3dZYWNOc0hmc2lJUDN2WG96SDRfRndfMFBidmExM2gyX1pObUc4ZERLT1B3?oc=5","date":"2025-09-25","type":"pipeline","source":"Börsen-Zeitung","summary":"Bayer wants Pharmaceuticals Division to be in the global top ten - Börsen-Zeitung","headline":"Bayer wants Pharmaceuticals Division to be in the global top ten - Börsen","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQQmVGNW9wbjFQQ3NmcDlsN3FTaXdnYzkzWFN4ZHFRcV9BUnpGZldSaDN3NGtPdU1SX2RSNG5FWlhHcUU3aTdkWlFpR3ZJTl93M0dob3Y5VlFjWDVUNFh1TmVRcjI3U3lLSk9fd055ODlKVDlXQmd2eGR5MVdoS0NNNDAxZXpubWVZYlRuSy1DSXFodVNLWVMwa0drVQ?oc=5","date":"2025-09-22","type":"trial","source":"PharmaTimes","summary":"First patient treated in pivotal trial of Parkinson’s cell therapy - PharmaTimes","headline":"First patient treated in pivotal trial of Parkinson’s cell therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxORkxrMVl4LXRKMXJod1ZZdk5ON045dHAtaVh5YUNqc2oxYVBrV19SMnM1MHJ1MmM1ZnZVZm9aSmRzZVNEQjhsTVRDUFdXNll3YTNuTWFQRk1peGpYU1c5SldZS2IxOGU0M3Z6cTlqVGExTUhIQ2F1Ull6cEpOcVJTLWJrVjEzeU43TkZGakhjaUQyVjQxR0lvelBSMlZvcDE0QnJhTHVTTmc0NTNTYl9faTRB?oc=5","date":"2025-06-26","type":"pipeline","source":"The Pharma Letter","summary":"BlueRock refocuses pipeline, trims staff and shutters Cambridge labs - The Pharma Letter","headline":"BlueRock refocuses pipeline, trims staff and shutters Cambridge labs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE83Tno4NFB2amFmMlBSOVlZU0ZDbWl0VUpUdGNyRldSTjVwU1Z3S0VYdGNuWTY5T1NRNmRtUThwOVJIeWpVNlJXZTRQZjBadUxrNUY4?oc=5","date":"2025-06-25","type":"pipeline","source":"FirstWord Pharma","summary":"Bayer's cell therapy unit BlueRock cuts 50 staffers - FirstWord Pharma","headline":"Bayer's cell therapy unit BlueRock cuts 50 staffers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPMkhTWmxNbHVIMUg0NkpHUDlzd010cnBQcy1OUlFWUThrYTQxM0wxYmFoQ3hXRVlrZDBudlJhT0RrampLYUkwV3k2TDg0NHp4d3gwQ0lTRDBUUWhWRmpGSHBwS0NmMk1JTlZzSFR4eGhIRTE1NTV1Z0ZJUjZWdEJSU2hHYWQwMTFCWDNiWTNTYmtFaDdVNUNKZjNaSHR4Q3h5TXJ1VGJtdlczdw?oc=5","date":"2025-06-25","type":"pipeline","source":"Fierce Biotech","summary":"Bayer-owned BlueRock lays off 50 employees, shutters Cambridge research labs - Fierce Biotech","headline":"Bayer-owned BlueRock lays off 50 employees, shutters Cambridge research labs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxPR3hQNEVzV1V0SVJfOV90Z3RvT3FFbnJBcmJldVRJQlVfS2lOeVd3WXFidEhFQlE0NXEwQkVfdmFTUXQwTTJ1bURzUnpJdVBPTE1iNnFTelZWNnhSQ2NPY3NNYzVjcDZVV0x5T3ZES1NOQ1JCbHYzSm5QXzdmMzd6bVJFWE5IbjRtOXNqUjZYcnJzV3pNeGl4RGdCTl9IWWZVYkhCdGtTZ01jQzB1UDRYR2FsY25xNWN4ejYwb1l6bzBmX0ZCTzRoNi13?oc=5","date":"2024-01-23","type":"pipeline","source":"Contract Pharma","summary":"Fujifilm Cellular Dynamics, Opsis Therapeutics and BlueRock Therapeutics Form Agreement - Contract Pharma","headline":"Fujifilm Cellular Dynamics, Opsis Therapeutics and BlueRock Therapeutics Form Agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNR25TOHF3TFk4cFp3SXpJdkJPRl90S3E5aWpSZU45ZTV0aUI0aHdCQXB4ZUNjdmxzTzc2NGxfREgzYTJKeHlzRk9vcjBsWTBMSmNZczktOTR3WG1MTDFVdzJhMEh5TE1mOFhCb2MwNWVDelVhMkxvNHRQb3QtNG5vWFVfN1V0c2t4d1dVejVVb0tyRGNaa0FHNzdB?oc=5","date":"2023-10-10","type":"pipeline","source":"Fierce Pharma","summary":"Bayer christens $250M cell therapy 'launch facility' in Berkeley - Fierce Pharma","headline":"Bayer christens $250M cell therapy 'launch facility' in Berkeley","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxONVB2UGI5dl8wbmtuV1FJeHktamI0RWlUWGpFUklodGtwVXJIUGwzOEFKb2VaWFpSQmlWVmFPRm81RG9nb0QwcVF5MzRZV1RmeGlKeVRLM2xKWjlBR2pXcE9TMFBFR0dCQm9TaVZrVlhmSmZyNVRaT05TR25TWXVZaVFKNHdCcWlZWFJodUs4Smh1YXZiYkVQV0daeDY?oc=5","date":"2023-08-28","type":"trial","source":"BioPharma Dive","summary":"Bayer reports positive early data for Parkinson’s cell therapy - BioPharma Dive","headline":"Bayer reports positive early data for Parkinson’s cell therapy","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPOVN2SVlwMnhjbWVOVURuaGdEZjB6TE15anR3RXV4TUtqMVYwUWJ1SkUtNTV6Z1VBVUNBUVVjZEo0eTh4V1hMQ2VtS2dyYjBCVW1fOUFpbXFzY3dpMU9fYkU2WHpWOENnUGd2SnhxdS11RzlGX2xXQWQ3X2pIS2NES3lRWjE1UjJUU2xFUEFOeG9PejR4c04weXdnQ1ZVSGFPS1N6enB0ODlzX1IybktBbEVTVmF2NXNVeU83U2ZxU3lGdFlZSkpB?oc=5","date":"2017-03-13","type":"pipeline","source":"Pharmaceutical Technology","summary":"BlueRock Therapeutics: Ontario’s home-grown stem cell contender - Pharmaceutical Technology","headline":"BlueRock Therapeutics: Ontario’s home-grown stem cell contender","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}